• Innovent Biologics

  Participated · Series D · Nov 2016

  Innovent Biologics is a Hong Kong-based biotech that develops and manufactures affordable complex biopharmaceutical products. Founded in August 2011 by Dr. Michael Yu, the company has built a portfolio targeting cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. It currently has 16 molecules in research, seven in clinical development, four in Phase III and one with a BLA submitted to the CFDA. Five molecules have been selected under the national mega innovative program and one received a precision medicine research grant under China's National Key R&D Plan. Innovent has a large-scale manufacturing base compliant with CFDA, FDA and EMA GMP standards. The company intends to use the funds to speed up and expand clinical programs and to build a commercial team. Innovent Biologics is a Shanghai, China–based biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of biologics. Founded in August 2011 by Michael Yu, Ph.D., the company has built a portfolio of 12 product candidates targeting cancer, autoimmune disorders, ophthalmology and cardiovascular diseases. Innovent has filed eight IND applications and has four products in clinical development, three of which are in phase 3 trials. The company operates under rigorous cGMP requirements and is expanding its manufacturing capacity. It intends to use new funding to continue development of innovative biopharmaceutical products, expand manufacturing, and support ongoing operations. Innovent Biologics is a Shanghai-based biopharmaceutical company dedicated to the development and manufacturing of complex biologics. Led by co-founder, president and CEO Michael Yu, the company is advancing an internal pipeline of eight antibody products, including one approved IND and four additional filed applications. Innovent aims to market its portfolio in the Chinese market and internationally while meeting EMEA and FDA/cGMP standards. Its strategy combines advancing proprietary biologic drugs with establishing in- and out-licensing agreements with global pharmaceutical and biotech companies. The company plans to use newly raised funds to advance its pipeline and grow operations. Innovent raised capital to support these plans and expand its development and manufacturing activities.

No current team members are available.